Analgesics - Market Insights, Competitive Landscape, and Market Forecast - 2027

The market is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases and rising demand of analgesics for the treatment of mild to moderate pain.

The global analgesics market was valued at USD 30,599 million in 2021, growing at a CAGR of 6.84% during the forecast period from 2022 to 2027 to reach USD 45,389 million by 2027. The analgesics market is slated to witness prosperity owing to the increasing prevalence of orthopedic, cancer, and other chronic diseases, the rising demand for analgesics for the treatment of mild to moderate pain, the growing burden of the geriatric population, and the growing focus on improving the safety, efficacy, and usability of analgesics for people are further expected to result in the appreciable revenue growth in the analgesics market during the forecast period (2022-2027).

Analgesics Market Dynamics:

According to the World Health Organization (WHO) 2022, globally nearly 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, and 1.09 million cases of stomach cancer were reported in 2020.

The rising prevalence of orthopedic diseases such as osteoarthritis, rheumatoid arthritis, and others is another important driver for the analgesics market. According to World Health Organization (WHO) 2022, musculoskeletal conditions are the leading contributor to disability and worldwide around 1.71 billion people are suffering from musculoskeletal diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis, and others. According to WHO 2022, worldwide around 528 million people suffered from osteoarthritis in 2019. As per the same source, worldwide 18 million people had rheumatoid arthritis in 2019.

Osteoarthritis often referred to as degenerative or wear-and-tear arthritis affects the joints and eventually causes the smooth cartilage on the surface of the bones to wear away. Patients face significant pain, edema, and joint inflammation which limits their ability to move freely. Analgesics are thereby taken to treat the pain.

Additionally, the rising demand for analgesics for the treatment of mild to moderate pain such as in the case of toothache, headache, pain due to strenuous physical activity, period pain, and others is another factor accelerating the growth of the analgesics market.

However, growing concern over opioid abuse and stringent regulatory policies may act as a restraint in the market growth for analgesics.

The COVID-19 pandemic has slightly impacted the market for analgesics. During the initial stage of the pandemic, the sale of analgesics suffered a downfall owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. Also, owing to the strict lockdown rules many elective surgeries and diagnosis sessions were postponed, impacting the demand for analgesics. However, there were analgesics such as acetaminophen (paracetamol), and others were taken by people suffering from COVID for relieving the symptoms such as fever and pain. Moreover, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of vaccines to the public, and the increasing number of surgeries and diagnoses of chronic pain and inflammation-related diseases, the demand for analgesics is anticipated to grow and will do the same during the forecast period from 2022 - 2027.

Analgesics Market Segment Analysis:

Analgesics market by Product Type (Opioids and Non-Opioids), Drug Type (Prescription and OTC), Distribution Channels (Hospital Pharmacy & Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the analgesics market, the non-opioids category is projected to register a significant growth in revenue in the overall analgesics market during the forecast period (2022-2027). Non-opioid analgesics are suitable and effective for a wide variety of pain and inflammatory conditions including musculoskeletal pain due to rheumatic disorders. They seem to have fewer side effects associated with them than opioid analgesics.

The commonly used analgesics are acetaminophen (paracetamol), antidepressants such as duloxetine and amitriptyline, aspirin and other non-steroidal anti-inflammatory agents (NSAIDS), and topical agents such as lidocaine and capsaicin among others.

Acetaminophen is indicated for mild to moderate pain such as in case of headache, period pain, backaches, and others. It is regarded as the first line of therapy for pain and fever, particularly in the case of viral infections.

Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain, have antipyretic properties, prevent blood clots, and can reduce inflammation by blocking enzymes such as prostaglandins that are responsible for causing pain and inflammation in the body.

The increasing number of research studies related to the evaluation of the role of non-opioid analgesics is further going to enhance the demand for non-opioid analgesics. For instance, in November 2021, Northwestern University in collaboration with the National Institutes of Health (NIH) started a clinical study that aims to determine whether the treatment with Carbidopa/Levodopa and Naproxen in females with acute pain after a bunionectomy or toe fusion (24hrs, 48hrs and 5 days) will reduce pain when compared with females receiving Placebo and Naproxen.

Therefore, owing to the above-mentioned factors, the non-opioids category is expected to generate considerable revenue thereby pushing the overall growth of the global analgesics market during the forecast period.

North America is expected to dominate the overall Analgesics Market:

Among all the regions, North America is expected to lead in revenue generation in the global analgesics market. This can be due to factors including the prevalence of chronic and infectious diseases such as orthopedic, cardiovascular, tuberculosis, and cancer among others, the increasing old age population, and the presence of key companies involved in the development of analgesics, and others.

The rising prevalence of arthritis in the US is the major factor responsible for the growth of the analgesics market in the region. As per the Centers for Disease Control and Prevention (CDC) 2021, it has been estimated that there will be around 78.4 million people suffering from doctor-diagnosed arthritis by 2040, and out of that two-thirds will be the women population.

As per the same source, an estimated 34.6 million adults will face arthritis-attributable activity limitations in the US by 2040. As per Arthritis Foundation 2021, around 1.5 million people have rheumatoid arthritis in the United States.

Moreover, as per the figures mentioned by the American Cancer Society 2021, it was estimated that 1.9 million new cancer cases have been diagnosed in the United States in 2021. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) in 2021, around 1,752,735 new cases of cancer were reported in the US in 2019.

Along with the presence of a large patient pool in the country, the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the analgesics market in the United States during the forecast period.

For example, in October 2021, Esteve Pharmaceuticals received the US Food and Drug Administration (FDA) clearance for SEGLENTIS® (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Therefore, the above-mentioned factors are expected to bolster the growth of the analgesics market in the United States during the forecast period.

Analgesics Market Key Players:

Some of the key market players operating in the Analgesics market include Novartis AG, Pfizer Inc., Bayer AG, AbbVie Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi, Assertio Holdings, Inc., Janssen Pharmaceuticals, Inc., GSK plc., Perrigo Company plc., Mallinckrodt, Purdue Pharma L.P., Abbott, Reckitt Benckiser Group PLC., Fresenius Kabi USA, Lilly, Hikma Pharmaceuticals PLC, Heron Therapeutics, Inc., and others.

Recent Developmental Activities in the Analgesics Market:

• In November 2021, Pacira Biosciences announced the acquisition of flexion therapeutics and strengthened its leadership position in non-opioid pain management.
• In August 2020, Trevena, Inc., received US FDA approval for an intravenous opioid analgesic OLINVYK.

Key Takeaways from the Analgesics Market Report Study

• Market size analysis for current analgesics market size (2021), and market forecast for 5 years (2022-2027)
• The effect of the COVID-19 pandemic on this market is significant. to capture and analyze suitable indicators, our experts are closely watching the analgesics market.
• Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global analgesics market.
• Various opportunities available for the other competitor in the analgesics market space.
• What are the top-performing segments in 2021? How these segments will perform in 2027?
• Which are the top-performing regions and countries in the current analgesics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for analgesics market growth in the coming future?

Target Audience who can be benefited from this Analgesics Market Report Study

• Analgesics products providers
• Research organizations and consulting companies
• Analgesics -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in analgesics
• Various distribution channels want to know more about the analgesics market and the latest product innovations in the analgesics market.

Frequently Asked Questions for the Analgesics Market:

1. What are Analgesics?

Analgesics, commonly known as painkillers are medications intended for reducing and relieving pain caused because of different conditions including headache, injury, surgery, arthritis, or any other disease.

2. What is the market for global Analgesics?

The global analgesics market was valued at USD 30,599 million in 2021, growing at a CAGR of 6.84% during the forecast period from 2022 to 2027 to reach USD 45,389 million by 2027.

3. What are the drivers for the global analgesics market?

The analgesics market is slated to witness prosperity owing to factors such as the increasing prevalence of orthopedic, cancer, and other chronic diseases, rising demand for analgesics for the treatment of mild to moderate pain, the growing burden of the geriatric population, and the growing focus on improving the safety, efficacy, and usability of analgesics for people is further expected to result in the appreciable revenue growth in the analgesics market during the forecast period (2022-2027).

4. Who are the key players operating in the global analgesics market?

Some of the key market players operating in the analgesics market include Novartis AG, Pfizer Inc., Bayer AG, AbbVie Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Sanofi, Assertio Holdings, Inc., Janssen Pharmaceuticals, Inc., GSK plc., Perrigo Company plc., Mallinckrodt, Purdue Pharma L.P., Abbott, Reckitt Benckiser Group PLC., Fresenius Kabi USA, Lilly, Hikma Pharmaceuticals PLC, Heron Therapeutics, Inc., and others.

5. Which region has the highest share in the analgesics market?

North America is expected to dominate the overall analgesics market during the forecast period, 2022 to 2027. This can be ascribed to the increasing prevalence of orthopedic, cancer, and other diseases responsible for causing chronic and acute pain, the increasing geriatric population, a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.


This product will be delivered within 3-5 business days.